BioCentury
ARTICLE | Company News

G-BA rebuffs Lyxumia for Type II diabetes

September 5, 2013 11:48 PM UTC

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Type II diabetes drug Lyxumia lixisenatide from Sanofi (Euronext:SAN; NYSE:SNY) has "no additional benefit" over comparators. The assessment is in line with a June preliminary assessment from Germany's Institute for Quality and Efficiency in Healthcare (IQWiG). Drugs that do not have an additional benefit are added to the reference pricing system, which gives a similar base price to all comparable drugs. If there is no reference, the company negotiates a price no higher than that of the comparator (see BioCentury Extra, June 17). ...